Free PANRE Practice Questions

Reproductive PANRE practice questions

10 free, board-style Reproductive questions for the PANRE, each with the correct answer and a complete explanation. No email, no account required.

Reproductive is 5% of the PANRE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.

Question 1ReproductiveMedium
A 24-year-old sexually active woman presents with several days of lower abdominal pain and mucopurulent cervical discharge. She is not pregnant and has no intrauterine device. On pelvic examination there is cervical motion tenderness and bilateral adnexal tenderness, and her temperature is 38.1 C (100.6 F). Which of the following is the most likely diagnosis?
  • ACandidal vaginitis
  • BPelvic inflammatory disease
  • CTrichomoniasis
  • DBacterial vaginosis
  • EMucopurulent cervicitis
Reveal answer & full explanation
Correct answer: B — Pelvic inflammatory disease
  • ACandidal vaginitis
  • BPelvic inflammatory disease✓
  • CTrichomoniasis
  • DBacterial vaginosis
  • EMucopurulent cervicitis

Why Pelvic inflammatory disease is correct

  • Pelvic inflammatory disease (PID) is a clinical diagnosis in a sexually active woman with pelvic or lower abdominal pain plus at least one of: cervical motion tenderness, uterine tenderness, or adnexal tenderness
  • This patient has cervical motion tenderness, bilateral adnexal tenderness, mucopurulent cervical discharge, and fever, indicating ascending genital tract infection
  • Empiric treatment is started on clinical grounds to prevent tubal damage; per current CDC guidance the outpatient regimen is ceftriaxone IM plus doxycycline plus metronidazole

Why the others are wrong

  • Bacterial vaginosis — thin gray discharge with a fishy odor and no cervical motion tenderness, adnexal tenderness, or fever; choosing it is buzzword-matching on vaginal discharge while ignoring the upper-tract signs
  • Candidal vaginitis — thick white discharge and vulvovaginal pruritus without cervical motion or adnexal tenderness; premature closure on a common vaginitis
  • Trichomoniasis — frothy discharge and possible cervicitis, but it does not produce bilateral adnexal and cervical motion tenderness with fever; anchoring on discharge alone misses the upper-tract findings
  • Mucopurulent cervicitis — the mucopurulent cervical discharge fits, which is why it tempts, but cervicitis is a lower-tract infection and does not account for the cervical motion tenderness, bilateral adnexal tenderness, and fever, which mark ascending spread; stopping at the cervix is premature closure that undertreats an infection needing the PID regimen
Question 2ReproductiveMedium
A 29-year-old woman presents with a 3-year history of progressively worsening dysmenorrhea, deep dyspareunia, and chronic pelvic pain. She has been unable to conceive after 18 months of unprotected intercourse. Pelvic exam reveals tender uterosacral nodularity and a fixed, retroverted uterus. Transvaginal ultrasound shows a 4-cm right ovarian cyst with homogeneous low-level internal echoes. Empiric NSAIDs and combined oral contraceptives have provided only partial relief. Which of the following is the most appropriate test to establish a definitive diagnosis?
  • AEndometrial biopsy
  • BSerum CA-125 assay
  • CHysterosalpingography
  • DLaparoscopy with biopsy
  • EPelvic MRI with contrast
Reveal answer & full explanation
Correct answer: D — Laparoscopy with biopsy
  • AEndometrial biopsy
  • BSerum CA-125 assay
  • CHysterosalpingography
  • DLaparoscopy with biopsy✓
  • EPelvic MRI with contrast

Why laparoscopy with biopsy is correct

  • Definitive diagnosis of endometriosis requires direct visualization of endometriotic implants at laparoscopy with histologic confirmation by biopsy.
  • Laparoscopy also allows simultaneous staging and surgical treatment: excision or ablation of lesions and lysis of adhesions.
  • This patient has classic clinical and imaging features of endometriosis: cyclic pelvic pain, deep dyspareunia, infertility, uterosacral nodularity, and an ovarian endometrioma on ultrasound.

Why the others are wrong

  • Serum CA-125 assay — may be elevated in endometriosis but is nonspecific (also elevated in PID, ovarian cancer, fibroids, pregnancy) and lacks sensitivity for mild disease; not diagnostic.
  • Endometrial biopsy — samples the eutopic lining of the uterine cavity, which is normal in endometriosis; the implants sit on peritoneum, ovaries, and uterosacral ligaments, so this samples the wrong compartment.
  • Pelvic MRI with contrast — helpful for mapping deep infiltrating endometriosis preoperatively but does not provide tissue diagnosis.
  • Hysterosalpingography — tempting given her 18 months of infertility because it assesses tubal patency and the uterine cavity, but it opacifies only the lumen of the uterus and tubes and cannot visualize or sample peritoneal, ovarian, or uterosacral implants; not diagnostic.

Additional high-yield points

  • Clinical and imaging findings often suggest endometriosis and may justify empiric medical therapy, but the formal diagnosis still rests on laparoscopic visualization with biopsy.
Question 3ReproductiveMedium
A 28-year-old woman with obesity has oligomenorrhea, hirsutism, and acne. Pelvic ultrasound shows bilateral ovaries each with >=20 follicles. Laboratory studies show an elevated LH (luteinizing hormone):FSH (follicle-stimulating hormone) ratio and a mildly elevated free testosterone. Which of the following is the most appropriate first-line management?
  • ASpironolactone therapy
  • BGlucocorticoid replacement
  • CLifestyle modification
  • DLaparoscopic ovarian drilling
  • EEstrogen replacement
Reveal answer & full explanation
Correct answer: C — Lifestyle modification
  • ASpironolactone therapy
  • BGlucocorticoid replacement
  • CLifestyle modification✓
  • DLaparoscopic ovarian drilling
  • EEstrogen replacement

Why lifestyle modification is correct

  • Oligomenorrhea, clinical and biochemical hyperandrogenism (hirsutism, acne, elevated free testosterone), and polycystic ovarian morphology satisfy the Rotterdam criteria (2 of 3) for polycystic ovary syndrome.
  • In a patient with obesity, lifestyle modification with 5-10% weight loss is first-line: it lowers androgens, improves insulin sensitivity, and restores ovulation in many patients.
  • Combined oral contraceptives, metformin, and letrozole are added for menstrual regulation, insulin resistance, and ovulation induction respectively, but behavioral change comes first.

Why the others are wrong

  • Estrogen replacement — these patients are estrogen-replete; unopposed estrogen would worsen endometrial risk and does not treat hyperandrogenism. Sets the confused-with-hypoestrogenism trap.
  • Glucocorticoid replacement — reserved for adrenal causes of hyperandrogenism such as non-classic congenital adrenal hyperplasia; the LH:FSH ratio and ovarian morphology point to an ovarian source. Sets the confused-with-CAH trap.
  • Laparoscopic ovarian drilling — a later-line option for ovulation induction in patients resistant to letrozole or clomiphene, and it addresses neither the metabolic driver nor the hirsutism. Sets the right-treatment-wrong-step trap.
  • Spironolactone therapy — the antiandrogen is tempting for hirsutism and acne, but it is a second-line agent, generally added when hirsutism persists after about 6 months of an estrogen-progestin contraceptive or used when one cannot be taken, and it requires reliable contraception because it can feminize a male fetus; it does not address the obesity and insulin resistance driving this presentation. Sets the treat-the-symptom trap.
Question 4ReproductiveMedium
A 16-year-old girl presents with severe lower abdominal pain and vaginal bleeding. Last menstrual period was 7 weeks ago. β-human chorionic gonadotropin (β-hCG) is 4,200 mIU/mL. Transvaginal ultrasound shows no intrauterine pregnancy and free pelvic fluid. BP is 82/54 mmHg and HR is 128/min. Which of the following is the most appropriate immediate management?
  • AEmergent surgical exploration
  • BDiagnostic laparoscopy after stabilization
  • CSingle-dose intramuscular methotrexate
  • DEmergent dilation and curettage
  • EBlood transfusion with inpatient observation
Reveal answer & full explanation
Correct answer: A — Emergent surgical exploration
  • AEmergent surgical exploration✓
  • BDiagnostic laparoscopy after stabilization
  • CSingle-dose intramuscular methotrexate
  • DEmergent dilation and curettage
  • EBlood transfusion with inpatient observation

Why Emergent surgical exploration is correct

  • This is a ruptured ectopic pregnancy with hemodynamic instability (BP 82/54 mmHg, HR 128/min), which is a surgical emergency.
  • Free pelvic fluid on ultrasound indicates hemoperitoneum from rupture.
  • No intrauterine pregnancy on transvaginal ultrasound (TVUS) with β-human chorionic gonadotropin (β-hCG) of 4,200 mIU/mL — above even a conservatively high discriminatory level (about 3,500 mIU/mL) — raises high suspicion for ectopic pregnancy.
  • Management: immediate IV access, type and crossmatch, fluid resuscitation, and emergent operating room for salpingectomy.

Why the others are wrong

  • Blood transfusion with inpatient observation — Transfusion supports the circulation but provides no source control; hemorrhage from the ruptured tube continues until it is operatively removed, so resuscitation must accompany surgery rather than substitute for it.
  • Diagnostic laparoscopy after stabilization — Diagnostic laparoscopy is the appropriate surgical approach when stable; however, with frank hemodynamic instability and suspected rupture, emergent exploration (which may require laparotomy) takes priority over a staged approach.
  • Single-dose intramuscular methotrexate — Contraindicated in this setting; methotrexate requires hemodynamic stability and no active bleeding.
  • Emergent dilation and curettage — uterine evacuation is the emergency procedure for hemorrhage from an incomplete miscarriage, and vaginal bleeding at 7 weeks invites that frame, but no intrauterine pregnancy on TVUS despite a β-hCG above the discriminatory level, together with free pelvic fluid and shock, places the source of hemorrhage outside the uterus in a ruptured ectopic pregnancy; curettage cannot control it and only delays the operation that can.
Question 5ReproductiveMedium
A 16-year-old female has not yet started menstruation. She has normal breast development (Tanner IV) and pubic hair (Tanner III) but no menarche. She has a history of cyclic monthly lower abdominal pain. Exam shows a bluish bulging mass at the introitus. Which of the following is the most likely diagnosis?
  • AImperforate hymen
  • BTransverse vaginal septum
  • CTurner syndrome
  • DMullerian agenesis
  • EAndrogen insensitivity
Reveal answer & full explanation
Correct answer: A — Imperforate hymen
  • AImperforate hymen✓
  • BTransverse vaginal septum
  • CTurner syndrome
  • DMullerian agenesis
  • EAndrogen insensitivity

Why Imperforate hymen is correct

  • Imperforate hymen is the most common obstructive vaginal anomaly
  • Classic presentation: normal secondary sexual development plus cyclic lower abdominal pain (cryptomenorrhea) plus purplish-blue bulging hymen (hematocolpos), all present in this patient
  • Ultrasound confirms hematocolpos
  • Treatment: cruciate or annular hymenotomy under anesthesia to allow drainage of accumulated blood; long-term prognosis is excellent

Why the others are wrong

  • Transverse vaginal septum — also obstructs menstrual outflow and causes cyclic pain with primary amenorrhea, but the obstruction lies higher in the vaginal canal, so the introitus appears normal rather than showing a bulging bluish membrane
  • Mullerian agenesis — Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH) has absent uterus and upper vagina; there is no hymenal bulge and no cyclic pain because there is no functioning uterine endometrium
  • Turner syndrome — associated with primary amenorrhea but presents with absent or minimal secondary sexual development (streak gonads), short stature, and webbed neck, not a bulging hymenal mass
  • Androgen insensitivity — like Mullerian agenesis, complete androgen insensitivity causes primary amenorrhea with normal breast development, but these 46,XY patients have sparse or absent pubic hair, a blind vaginal pouch, and no uterus, so there is no cyclic pain or bulging hematocolpos at the introitus
Question 6ReproductiveMedium
A 45-year-old female has not had a period in 14 months. She has hot flashes, night sweats, vaginal dryness, dyspareunia, and urinary urgency. FSH is 68 IU/L. She is interested in treatment but concerned about breast cancer risk. She has no personal or family history of breast cancer. Her last mammogram was normal. Which of the following is the most appropriate therapy for her genitourinary symptoms?
  • ADaily oral raloxifene
  • BSystemic oral estrogen
  • CLow-dose vaginal estrogen
  • DTestosterone cream
  • ESelective serotonin reuptake inhibitor
Reveal answer & full explanation
Correct answer: C — Low-dose vaginal estrogen
  • ADaily oral raloxifene
  • BSystemic oral estrogen
  • CLow-dose vaginal estrogen✓
  • DTestosterone cream
  • ESelective serotonin reuptake inhibitor

Why Low-dose vaginal estrogen is correct

  • Genitourinary syndrome of menopause (GSM) encompasses vulvovaginal atrophy plus urinary symptoms from estrogen deficiency; it affects 50-80% of postmenopausal women.
  • Low-dose vaginal estrogen (cream, ring Estring, tablet/suppository Vagifem) has minimal systemic absorption, causes no endometrial stimulation at low doses, requires no progestogen, and per American College of Obstetricians and Gynecologists (ACOG) and North American Menopause Society (NAMS) guidance may be considered even in breast cancer survivors whose symptoms persist despite nonhormonal therapy, after shared decision-making with their oncologist.
  • It is the preferred therapy when the treatment target is vaginal dryness, dyspareunia, and urinary urgency, particularly in a woman worried about breast exposure.

Why the others are wrong

  • Selective serotonin reuptake inhibitor — SSRIs address vasomotor symptoms (hot flashes) but do not treat genitourinary symptoms such as vaginal dryness and dyspareunia (confused-with vasomotor therapy).
  • Testosterone cream — testosterone is not FDA approved for genitourinary syndrome of menopause and is not a first-line therapy for vulvovaginal atrophy (right-concept-wrong-hormone).
  • Systemic oral estrogen — systemic therapy exposes the breast and endometrium far more than local therapy and is not required to relieve genitourinary symptoms, which respond to low-dose vaginal estrogen even in women already taking systemic hormone therapy (overtreatment for a local target).
  • Daily oral raloxifene — a selective estrogen receptor modulator (SERM) that appeals to a woman worried about breast cancer because it lowers invasive breast cancer risk, but it has no estrogenic effect on the vaginal epithelium, so it does not relieve dryness or dyspareunia and can worsen hot flashes (confused-with ospemifene).

Additional high-yield points

  • Ospemifene (Osphena): oral selective estrogen receptor modulator (SERM), effective for dyspareunia, may cause hot flashes, contraindicated in breast cancer.
  • Prasterone (dehydroepiandrosterone (DHEA) vaginal suppository, Intrarosa): local DHEA converted to estrogen and androgen in vaginal tissue.
  • Non-hormonal lubricants: appropriate for mild symptoms or women who cannot use any estrogen.
Question 7ReproductiveMedium
A 58-year-old woman presents with a 4-month history of a scaly, erythematous, eczematous lesion involving the right nipple and areola. She reports itching, mild burning, and intermittent serous discharge from the nipple. She has tried over-the-counter hydrocortisone with no improvement. Exam shows a unilateral, well-demarcated, crusted plaque on the nipple with areolar involvement; no palpable breast mass or axillary lymphadenopathy. Which of the following is the most likely diagnosis?
  • ASeborrheic dermatitis
  • BPaget disease of the breast
  • CNipple candidiasis
  • DInflammatory breast cancer
  • EAtopic dermatitis of the nipple
Reveal answer & full explanation
Correct answer: B — Paget disease of the breast
  • ASeborrheic dermatitis
  • BPaget disease of the breast✓
  • CNipple candidiasis
  • DInflammatory breast cancer
  • EAtopic dermatitis of the nipple

Why Paget disease of the breast is correct

  • Mammary Paget disease is an intraepidermal adenocarcinoma of the nipple, almost always associated with an underlying ductal carcinoma in situ or invasive ductal carcinoma.
  • It classically presents as a unilateral, chronic, eczematous or scaling lesion of the nipple that extends onto the areola, often with itching, burning, or bloody/serous discharge.
  • A hallmark feature is failure to respond to topical steroids.
  • Diagnosis is confirmed by full-thickness nipple skin biopsy showing Paget cells; bilateral mammography and breast MRI are then obtained to evaluate the underlying parenchyma.
  • Unilateral involvement, steroid-refractory course, and nipple-then-areola spread are the defining hallmarks.

Why the others are wrong

  • Nipple candidiasis — most often seen in lactating women, presents with intense burning during/after feeds and shiny erythema, not a chronic crusted plaque (confused-with intertrigo).
  • Seborrheic dermatitis — favors scalp, nasolabial folds, and chest; nipple involvement is uncommon and typically bilateral (anchoring on "scaly").
  • Atopic dermatitis of the nipple — typically bilateral, occurs in patients with an atopic history, and responds to topical steroids (premature closure on benign eczema).
  • Inflammatory breast cancer — also a breast cancer with skin changes, but it causes rapidly progressive erythema, edema, and peau d'orange over a large part of the breast (at least one third), not a well-demarcated crusted plaque confined to the nipple and areola (confused-with other skin-involving breast cancer).

Additional high-yield points

  • Pearl: any unilateral nipple eczema lasting more than several weeks or unresponsive to topical steroids requires biopsy to rule out Paget disease.
Question 8ReproductiveMedium
A 52-year-old woman presents with daily hot flashes, night sweats, and difficulty sleeping that have persisted for the past year and are interfering with her work. She also reports vaginal dryness and pain with intercourse. Her last menstrual period was 18 months ago. She has no personal or family history of breast cancer, venous thromboembolism, or coronary artery disease, and she has not had a hysterectomy. Her blood pressure and BMI are normal. After counseling, she elects to start systemic menopausal hormone therapy, and she and her clinician prioritize the safest effective regimen. Which of the following hormone regimens is most appropriate for this patient?
  • ATransdermal estradiol plus micronized progesterone
  • BTransdermal estradiol plus medroxyprogesterone acetate
  • CConjugated estrogen plus medroxyprogesterone acetate
  • DTransdermal estradiol plus vaginal estradiol
  • EOral estradiol plus micronized progesterone
Reveal answer & full explanation
Correct answer: A — Transdermal estradiol plus micronized progesterone
  • ATransdermal estradiol plus micronized progesterone✓
  • BTransdermal estradiol plus medroxyprogesterone acetate
  • CConjugated estrogen plus medroxyprogesterone acetate
  • DTransdermal estradiol plus vaginal estradiol
  • EOral estradiol plus micronized progesterone

Why Transdermal estradiol plus micronized progesterone is correct

  • Amenorrhea for 18 months with disabling vasomotor symptoms (hot flashes, night sweats, sleep disruption) plus genitourinary symptoms establishes symptomatic menopause warranting systemic hormone therapy
  • She has an intact uterus, so systemic estrogen must be combined with a progestogen for endometrial protection; this regimen provides a complete combined estrogen-progestogen course
  • Transdermal estradiol bypasses hepatic first-pass metabolism and carries lower venous thromboembolism and stroke risk than oral estrogen, and micronized progesterone has a more favorable breast and metabolic profile than medroxyprogesterone acetate (NAMS/Menopause Society 2022)
  • When the explicit goal is the safest effective systemic therapy in an average-risk woman, the transdermal estradiol plus micronized progesterone regimen is the guideline-preferred single best choice

Why the others are wrong

  • Conjugated estrogen plus medroxyprogesterone acetate — a complete and guideline-valid combined regimen, but oral conjugated estrogen carries higher VTE/stroke risk and MPA has a less favorable breast/metabolic profile, so it is not the safest option for this average-risk patient (right-concept-higher-risk)
  • Transdermal estradiol plus medroxyprogesterone acetate — the estrogen route is the preferred one, but medroxyprogesterone acetate carries a less favorable breast and metabolic profile than micronized progesterone, so the pairing is not the safest effective regimen (right-route-wrong-progestogen)
  • Oral estradiol plus micronized progesterone — the progestogen is the preferred one, but oral estradiol undergoes hepatic first-pass metabolism and raises VTE and stroke risk relative to transdermal delivery (right-progestogen-wrong-route)
  • Transdermal estradiol plus vaginal estradiol — appeals because the transdermal route is the lower-risk one and vaginal estrogen targets her dryness and dyspareunia, but the regimen contains no progestogen, and systemic estrogen in a woman with an intact uterus must be paired with a progestogen to prevent endometrial hyperplasia and cancer (right-route-no-endometrial-protection)

Additional high-yield points

  • Uterus present → estrogen PLUS progestogen; uterus absent → estrogen alone
  • Transdermal estradiol carries lower VTE/stroke risk than oral estrogen and is preferred when minimizing thrombotic risk
  • Use the lowest effective dose for symptom control
Question 9ReproductiveMedium
A 27-year-old woman at 32 weeks gestation is brought to the ED after a motor vehicle collision in which she was the restrained driver. She reports lower abdominal pain and one episode of vaginal bleeding. Vitals: BP 108/68, HR 104, RR 18. Exam shows a tender, firm uterus with frequent low-amplitude contractions; fetal heart tones are 150 with late decelerations. Hemoglobin is 11.2 g/dL and fibrinogen is 220 mg/dL. Which of the following obstetric complications is most likely?
  • AUterine rupture
  • BPlacental abruption
  • CPreterm premature rupture of membranes
  • DAmniotic fluid embolism
  • EPlacenta previa
Reveal answer & full explanation
Correct answer: B — Placental abruption
  • AUterine rupture
  • BPlacental abruption✓
  • CPreterm premature rupture of membranes
  • DAmniotic fluid embolism
  • EPlacenta previa

Why Placental abruption is correct

  • Placental abruption is the most common serious obstetric complication of blunt maternal trauma
  • Shearing forces between the elastic uterus and the inelastic placenta cause decidual vessel disruption, producing retroplacental hematoma
  • Classic presentation: painful bleeding, uterine tenderness, frequent low-amplitude contractions, and nonreassuring fetal tracing (late decelerations)
  • Falling fibrinogen and tachycardia further support abruption-related consumptive coagulopathy

Why the others are wrong

  • Preterm premature rupture of membranes — presents with a gush of clear fluid and pooling on speculum exam, not with a tender, contracting uterus and late decelerations (confused-with another trauma-related presentation)
  • Uterine rupture — far less common in an unscarred uterus; typically presents with loss of fetal station, maternal hemodynamic collapse, and palpable fetal parts abdominally rather than a firm contracting uterus (anchoring on trauma)
  • Placenta previa — causes painless bleeding and a soft, nontender uterus and is not precipitated by trauma (right-concept-wrong-bleeding-source)
  • Amniotic fluid embolism — trauma plus a falling fibrinogen can suggest it, but amniotic fluid embolism presents abruptly with hypoxia, cardiovascular collapse, and fulminant DIC, usually during labor or just after delivery, whereas this patient is hemodynamically compensated without respiratory distress and has a tender, bleeding uterus (anchoring on the coagulopathy)

Additional high-yield points

  • Initial management: continuous fetal monitoring for at least 4 hours, type and crossmatch, Kleihauer-Betke testing, and Rh immunoglobulin if Rh negative
Question 10ReproductiveMedium
A 28-year-old female at 36 weeks gestation develops sudden severe right upper quadrant and epigastric pain, nausea, and headache. BP is 162/108. Urinalysis shows 3+ protein. Labs: AST 285, ALT 240, LDH 920, platelets 88K, hemoglobin 9.2 g/dL with schistocytes. Which of the following is the most likely diagnosis?
  • AAcute fatty liver of pregnancy
  • BImmune thrombocytopenic purpura
  • CAcute cholecystitis
  • DHELLP syndrome
  • EHemolytic uremic syndrome
Reveal answer & full explanation
Correct answer: D — HELLP syndrome
  • AAcute fatty liver of pregnancy
  • BImmune thrombocytopenic purpura
  • CAcute cholecystitis
  • DHELLP syndrome✓
  • EHemolytic uremic syndrome

Why HELLP syndrome is correct

  • HELLP is a severe variant of preeclampsia defined by Hemolysis, Elevated Liver enzymes, and Low Platelets.
  • Tennessee criteria are all met here: hemolysis (LDH above 600, schistocytes on smear), elevated liver enzymes (AST or ALT above 70), and platelets below 100K.
  • Classic presentation seen in this patient: RUQ/epigastric pain (liver capsule distension), nausea, headache, hypertension, and proteinuria at 34 weeks or beyond.
  • The microangiopathic hemolytic anemia (hemoglobin 9.2, schistocytes) plus thrombocytopenia distinguishes it from isolated liver or platelet disorders.

Why the others are wrong

  • Acute fatty liver of pregnancy — confused-with HELLP because both cause third-trimester liver dysfunction, but AFLP is marked by hypoglycemia, prolonged PT/coagulopathy, and encephalopathy rather than this MAHA-plus-thrombocytopenia picture.
  • Immune thrombocytopenic purpura — right-concept-wrong-setting: ITP causes isolated thrombocytopenia with no hemolysis (normal LDH, no schistocytes) and no severe hypertension or proteinuria.
  • Acute cholecystitis — anchoring on the RUQ pain and nausea, but cholecystitis lacks proteinuria, microangiopathic hemolytic anemia, and hypertension.
  • Hemolytic uremic syndrome — confused-with HELLP because both cause microangiopathic hemolysis with schistocytes and thrombocytopenia, but HUS is dominated by acute kidney injury and, when pregnancy-associated, usually presents postpartum; RUQ pain with marked transaminase elevation in a hypertensive, proteinuric woman at 36 weeks is the hepatic signature of HELLP.

Additional high-yield points

  • Complications: subcapsular liver hematoma/rupture, DIC, AKI, placental abruption, pulmonary edema.
  • Management: magnesium sulfate IV for seizure prophylaxis (4–6 g load then 1–2 g/hr); antihypertensives for severe hypertension (labetalol IV first-line, hydralazine IV, or nifedipine PO) targeting BP 140–155/90–105.
  • Delivery is definitive: above 34 weeks deliver promptly; at 27–34 weeks give antenatal steroids then deliver in 24–48 hours.
  • DIC support: fresh frozen plasma, cryoprecipitate, and platelets if below 50K or active bleeding.

That's 10 of 7,700+. Get the rest.

Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → See today's free PANRE question →

Reproductive PANRE practice: FAQ

Are these Reproductive PANRE practice questions free?

Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.

How much of the PANRE is Reproductive?

Reproductive makes up 5% of the PANRE content blueprint. FirstPassPA's timed PANRE exams are dealt to the same weights, so a practice exam carries the same share of Reproductive questions.

How should I use these questions?

Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Reproductive questions in the app, or take a full timed PANRE practice exam dealt to the blueprint weights.

Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.